SLC5A2 and type 2 diabetes mellitus: The analysis of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial, which examined the impact of the SGLT2 inhibitor empagliflozin on cardiovascular complications and death in patients with type 2 diabetes (T2D) at high risk for cardiovascular disease, surprised the world [2].